Exhibit 16.1
August 22, 2025
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Item 4.01 of Sagimet Biosciences Inc.’s Form 8-K dated August 22, 2025, and have the following comments:
| 1. | We agree with the statements made in the second paragraph and the fourth paragraph. |
| 2. | We have no basis on which to agree or disagree with the statements made in the first paragraph or the third paragraph. |
Yours truly,
/s/ DELOITTE & TOUCHE LLP